Trably C.,Service dObstetrique et de Gynecologie |
Rudigoz R.-C.,Service dObstetrique et de Gynecologie |
Dubernard G.,Service dObstetrique et de Gynecologie |
Huissoud C.,Service dObstetrique et de Gynecologie |
And 2 more authors.
Revue Francophone des Laboratoires | Year: 2010
Preeclampsia is a frequent pregnancy-specific disease that remains one of the first causes of maternal and foetal death. Preeclampsia is defined by a systolic arterial blood pressure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg associated to a significant proteinuria > 0,3 g/24 h occurring after 20 weeks of pregnancy.Physiological mechanisms underlying pre-eclampsia are complex and remain imperfectly known in spite of recent progress. Screening and monitoring of preeclampsia are based on clinical and biological foetal-maternal survey. Maternal complications are associated with biologic al changes defining severe forms of preeclampsia. HELLP syndrome represents the most frequent and one of the most threatening complications of the disease that may severely impact both maternal and foetal prognosis.Presently, there is no specific and reliable test to early identify women at higher risk of preeclampsia. Nevertheless, first and second trimester serum screening for Down's syndrome may help in detecting women with increased risk of pregnancy-related hypertension justifying specific monitoring of pregnancy. © 2010 - Elsevier Masson SAS - Tous droits réservés. Source